TABLE 1.
Properties of zonisamide.
| Zonisamide | |
| Alternative names | AD-810, ZonegranR |
| ATC code | N03A (antiepileptic drugs), N04 (antiparkinsonian drugs) |
| Mechanisms | See Figure 2 |
| Prescription | |
| Route | Orally |
| Recommended dosage | 25, 50 mg |
| Administration mode | Once daily |
| Indication | |
| Recommended as add-on treatment in patients with Parkinson disease | |
| Pharmacokinetics (Uno et al., 1979; Ito et al., 1982; Matsumoto et al., 1983; Stiff et al., 1992; Nakasa et al., 1998; Ohmori et al., 1998; Sills and Brodie, 2007; Yang and Perry, 2009) | |
| Mean maximum plasma concentration (Cmax) | 2.3–12 mg/ml |
| Median time (tmax) | 2.4–3.6 h |
| Absolute bioavailability | Nearly 100% |
| Apparent volume of distribution | 1.1–1.7 L/kg |
| Clearance | 1.91 L/h |
| Elimination half-life | 49.7–62.5 h |
| Pivotal trials | See Table 2 |
| Common adverse events | See Table 3 |
ATC, Anatomical Therapeutic Chemical.